New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Trial ID or NCT#
Status
Purpose
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Official Title
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Eligibility Criteria
- - Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI. - Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia. - Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.
- -Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.
Investigator(s)
Contact us to find out if this trial is right for you.
CONTACT
Mei-Sze Chua
(650) 724-3525
View on ClinicalTrials.gov
About this Clinical Trial
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Your Message Will Go To
Mei-Sze Chua650-724-3525